Papers/PMID:32932644
L-Carnitine's Effect on the Biomarkers of Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Nutrients2020The record
3 findings · 1 compound · 3 endpoints · 2 null
What it reported
How to read these marksWhat moved
1 finding
(R)-carnitine — decreases systolic blood pressure (setting unspecified)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“L-carnitine supplementation was related to a mean decrease in SBP of –7.41 mmHg (95% CI: −14.59 to −0.23, p = 0.04).”
Quoted verbatim from L-Carnitine's Effect on the Biomarkers of Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Dose
- 0.75 to 3 g/day across included RCTs, 8 to 24 weeks
- Population
- Adults in nine RCTs (diabetes mellitus, non-alcoholic steatohepatitis, knee osteoarthritis, hemodialysis); two RCTs contributed SBP data; controls received no L-carnitine
L-Carnitine's Effect on the Biomarkers of Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2020PMID:32932644Permalink
What did not
2 findings
(R)-carnitine — no detected effect on fasting blood glucose
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Similarly, FBS, TG, and HDLc with L-carnitine intervention presented no significant difference between the intervention and control groups.”
Quoted verbatim from L-Carnitine's Effect on the Biomarkers of Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Dose
- 0.75 to 3 g/day across included RCTs, 8 to 24 weeks
- Population
- Adults in nine RCTs (diabetes mellitus, non-alcoholic steatohepatitis, knee osteoarthritis, hemodialysis); five RCTs contributed FBS data; whole-population estimate
L-Carnitine's Effect on the Biomarkers of Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2020PMID:32932644Permalink
(R)-carnitine — no detected effect on triglycerides
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×1“Similarly, FBS, TG, and HDLc with L-carnitine intervention presented no significant difference between the intervention and control groups.”
Quoted verbatim from L-Carnitine's Effect on the Biomarkers of Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Dose
- 0.75 to 3 g/day across included RCTs, 8 to 24 weeks
- Population
- Adults in nine RCTs (diabetes mellitus, non-alcoholic steatohepatitis, knee osteoarthritis, hemodialysis); six RCTs contributed TG data; whole-population estimate
L-Carnitine's Effect on the Biomarkers of Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2020PMID:32932644Permalink